Nyxoah Future Growth
Future criteria checks 2/6
Nyxoah is forecast to grow earnings and revenue by 10.2% and 46.4% per annum respectively while EPS is expected to decline by 2.6% per annum.
Key information
10.2%
Earnings growth rate
-2.6%
EPS growth rate
| Medical Equipment earnings growth | 18.6% |
| Revenue growth rate | 46.4% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 16 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 87 | -55 | -59 | -46 | 6 |
| 12/31/2025 | 36 | -69 | -84 | -67 | 8 |
| 12/31/2024 | 9 | -61 | -66 | -60 | 8 |
| 12/31/2023 | 4 | -43 | -56 | -45 | N/A |
| 9/30/2023 | 4 | -46 | -57 | -43 | N/A |
| 6/30/2023 | 3 | -44 | -56 | -42 | N/A |
| 3/31/2023 | 3 | -36 | -50 | -34 | N/A |
| 12/31/2022 | 3 | -31 | -45 | -29 | N/A |
| 9/30/2022 | 2 | -24 | -41 | -26 | N/A |
| 6/30/2022 | 2 | -27 | -42 | -27 | N/A |
| 3/31/2022 | 1 | -29 | -40 | -27 | N/A |
| 12/31/2021 | 1 | -28 | -37 | -25 | N/A |
| 9/30/2021 | 1 | -25 | -31 | -19 | N/A |
| 6/30/2021 | 0 | -21 | -23 | -11 | N/A |
| 3/31/2021 | 0 | -16 | -21 | -10 | N/A |
| 12/31/2020 | 0 | -12 | -18 | -7 | N/A |
| 9/30/2020 | 0 | -8 | -16 | -7 | N/A |
| 6/30/2020 | N/A | -5 | -14 | -7 | N/A |
| 3/31/2020 | N/A | -4 | -12 | -6 | N/A |
| 12/31/2019 | N/A | -4 | -12 | -6 | N/A |
| 12/31/2018 | N/A | -9 | -8 | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NYXH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NYXH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NYXH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NYXH's revenue (46.4% per year) is forecast to grow faster than the Belgian market (5.8% per year).
High Growth Revenue: NYXH's revenue (46.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NYXH's Return on Equity is forecast to be high in 3 years time